Cover Image

Health technology assessment and reimbursement of pharmaceuticals in Italy

The Italian healthcare system is historically structured by the difference in economic development between the northern and southern parts of this country. The Italian Medicines Agency (AIFA) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-li...

Full description

Saved in:

Bibliographic Details
Main Authors:	F. V. Gorkavenko (Author), V. V. Omelyanovskiy (Author), T. P. Bezdenezhnykh (Author), G. R. Khachatryan (Author)
Format:	Book
Published:	IRBIS LLC, 2019-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The health technology assessment system in Australia
by: V. V. Omelyanovskiy, et al.
Published: (2020)

Peculiarities of real-world data application for health technology assessment in Asian countries
by: B. B. Kondratyeva, et al.
Published: (2024)

Organizational structure and funding of health technology assessment agencies around the world
by: G. R. Khachatryan, et al.
Published: (2019)

Drug provision and health technology assessment in France
by: V. V. Omelyanovskiy, et al.
Published: (2020)

Real-world data: principles of use in decision making and in health technology assessment
by: V. V. Omelyanovskiy, et al.
Published: (2023)

The review of the foreign experience on the financing of innovative medical technologies
by: V. V. Omelyanovskiy, et al.
Published: (2020)

Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy
by: V. A. Lemeshko, et al.
Published: (2021)

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate
by: Elizabeth Docteur, et al.
Published: (2015)

Italy - a study case of medicines pricing and reimbursement
by: Valdete A. MELO, et al.
Published: (2022)

EARLY HEALTH TECHNOLOGIES ASSESSMENT - NEW APPROACH TO IMPROVING THE EFFICIENCY OF THE MEDICAL TECHNOLOGY DEVELOPMENT PROCESS
by: N. Z. Musina, et al.
Published: (2016)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
by: Sabine Vogler, et al.
Published: (2015)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
by: Michael Kossmeier, et al.
Published: (2021)

Organization and financial support of healthcare for public employees in the Russian Federation: a review of departmental health services in the Ministry of Defense
by: D. V. Lukyantseva, et al.
Published: (2019)

RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16
by: Alejandra Castanon, et al.
Published: (2024)

Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan
by: T. P. Bezdenezhnykh, et al.
Published: (2019)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10
by: Alex Simpson, et al.
Published: (2022)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12
by: Ben Bray, et al.
Published: (2023)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 11
by: Ben Bray, et al.
Published: (2023)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14
by: Benjamin D Bray, et al.
Published: (2024)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13
by: Benjamin D Bray, et al.
Published: (2023)

A comparative analysis of pricing and reimbursement systems between Italy and Bulgaria
by: Carmen Cannavale, et al.
Published: (2024)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15
by: Alejandra Castanon, et al.
Published: (2024)

Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022)

The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
by: Dumebi O Mordi, et al.
Published: (2015)

Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
by: David Elvira, et al.
Published: (2021)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017)

Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration
by: Bregtje W. Kamphuis, et al.
Published: (2021)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
by: Tomas Tesar, et al.
Published: (2021)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
by: Elizabeth Docteur, et al.
Published: (2015)

Affordability of in vivo gene therapy. Problems and potential solutions
by: V. V. Omelyanovskiy, et al.
Published: (2020)

Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies
by: Tetsuji Yamada
Published: (2017)

Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept
by: Dominik J. Wettstein, et al.
Published: (2021)

Implementation of health technology assessment at the stage of market access for pharmaceuticals in Ukraine
by: O. B. Piniazhko, et al.
Published: (2020)

Alternativas a la distribución de medicamentos y su retribución Alternatives to pharmaceutical distribution and reimbursement
by: R. Meneu
Published: (2002)

THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS
by: V. K. Fedyaeva, et al.
Published: (2017)

The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making; Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling"
by: Hansoo Kim, et al.
Published: (2021)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
by: Stafinski T, et al.
Published: (2011)

Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies
by: Mihajlo Jakovljevic, et al.
Published: (2017)